权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

PATHOPHYSIOLOGY OF CARBOHYDRATE-DEFICIET GLYCOPROTEIN SYNDROME

碳水化合物缺乏糖蛋白综合征的病理生理学

基本信息

批准号：
10670729
负责人：
OHNO Kousaku
金额：
$ 2.05万
依托单位：
TOTTORI UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
1998
资助国家：
日本
起止时间：
1998 至 1999
项目状态：
已结题

项目摘要

Carbohydrate-deficient glycoprotein syndrome (CDGS) is an autosomal recessive disorders characterized by appearance of serum asparagine-N-linked glycoprotein with defective sugar chain. The basic defect of CDGS type I has been identified in the phosphomannomutase 2 gene in 1997. Abnormal glycoproteins in CDGS have been identified only in serum glycoproteins. To identify intracellular glycosylation abnormalities, we have been studied in cultured fibroblasts from three Japanese patients with CDGS type I. In this project we have studied sugar chains of lysosomal enzymes synthesized in cultured fibroblasts. We have failed to identify the abnormal fractions with defective sugar chains in several lysosomal enzymes in media and in cells. Then we have studied intrecellular processing of β-hexosaminidase and found that protein and mRNA levels of a 55-kDa mature form of the α chain. It was suggested that intracellular processing of glycoproteins including b-hexosaminidase in CDG fibroblasts might be altered. In cultured fibroblasts we have studied a pathway to form full-sized lipid linked oligosaccharide (LLO) using labeled mannose and found patient fibroblasts required six times higher concentrations of mannose to form dull-sized LLO. Various reagents restoring the LLO syn thesis in CDGS type I fibroblasts were screened and the addition of dolichol was found to be most effective to restore the formation of the full-sized LLO. These phenomena may be due to activation of dolichol phosphomannose synthase by addition of dolichol, since the level of dolichol and LLO are decreased in CDGS type I fibroblasts as described in our previous paper (J Biol Chem 272, 6868-6875, 1997).

碳水化合物缺乏糖蛋白综合征（CDGS）是一种常染色体隐性遗传疾病，其特征是血清中出现糖链缺陷的天冬酰胺-N-连接糖蛋白。CDGS I型的基本缺陷已于1997年在磷酸甘露变位酶2基因中被鉴定。CDGS中的异常糖蛋白仅在血清糖蛋白中被鉴定。为了鉴定细胞内糖基化异常，我们在来自三名日本CDGS I型患者的培养成纤维细胞中进行了研究。在这个项目中，我们研究了在培养的成纤维细胞中合成的溶酶体酶的糖链。我们未能确定培养基和细胞中几种溶酶体酶中糖链缺陷的异常组分。然后，我们研究了β-氨基己糖苷酶的细胞内加工，发现55 kDa成熟形式的α链的蛋白质和mRNA水平。这表明，在CDG成纤维细胞的糖蛋白，包括b-氨基己糖苷酶的细胞内加工可能会改变。在培养的成纤维细胞中，我们研究了使用标记的甘露糖形成全尺寸脂质连接寡糖（LLO）的途径，并发现患者成纤维细胞需要六倍高浓度的甘露糖来形成暗色LLO。筛选了在CDGS I型成纤维细胞中恢复LLO合成的各种试剂，发现添加多萜醇对恢复全尺寸LLO的形成最有效。这些现象可能是由于通过添加多萜醇激活了多萜醇磷酸甘露糖合酶，因为如我们先前的论文（J Biol Chem 272，6868-6875，1997）中所述，在CDGS I型成纤维细胞中多萜醇和LLO的水平降低。